SCHEDULE 13G: Anson Funds Group Discloses 7.1% Stake in 180 Life Sciences Corp.

Anson Funds Management LP and its affiliates, including key individuals, have disclosed a beneficial ownership of 7.1% in 180 Life Sciences Corp., totaling 225,271 shares of common stock.

Summary

• Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing indicates beneficial ownership of 225,271 shares of Common Stock in 180 Life Sciences Corp.
• This ownership represents 7.1% of the outstanding Common Stock of 180 Life Sciences Corp.
• The percentage is calculated based on 3,176,999 Common Shares issued and outstanding, as reported in the Issuer's Prospectus Supplement filed on December 30, 2024.
• The Reporting Persons share both voting and dispositive power over these shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or outlook. It simply reports a significant stake.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future operations or financial performance.

Management Comments

• "By signing below each of the Reporting Persons certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and held in the Common course of business and were not acquired and were not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect."

Industry Context

This filing indicates a significant institutional investment in 180 Life Sciences Corp. by Anson Funds, a group known for its investment activities. While not directly related to broader industry trends, such a substantial stake by an investment firm can signal confidence or strategic interest in the biotechnology or life sciences sector, depending on the issuer's specific focus.

Stakeholder Impact

• Shareholders: The disclosure of a significant 7.1% stake by an institutional investor group may be viewed positively by other shareholders, potentially signaling confidence in the company or attracting further investor interest.

Key Dates

Keywords

180 Life Sciences Corp., Anson Funds Management LP, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing